BridgeMD
Study to evaluate the effectiveness, safety, and quality of life of Bilaxten, an allergy medication, in children
EU CTIS ID: 2024-519550-36-00
What this study is testing
To assess the efficacy of bilastine 10 mg ODT in children from ≥ 6 to < 12 years old with allergic rhinoconjunctivitis (AR), after 14 days of daily treatment, through the variation in AR symptoms, usinig a combined five symptoms score (mean change vs baseline in the T5CSS: sneezing, rhinorrhoea, nasal pruritus, tearing and ocular pruritus). Reflective AR symptoms will be collected daily, referring to the preceeding 12-24 hours, and these scores will be used fo the efficacy assessment.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participants of either sex (male or female) aged ≥ 6 and < 12 years with a body weight of at least 15 kg at the time of enrolment
- Participants must have a documented clinical history (at least 1 year) of AR and must present mild-moderate clinical symptoms at the time of inclusion in the study
- Participants with AR must have a positive skin reaction/RAST test documented in their clinical history within a year prior to the date of their inclusion in the study: a positive prick test (papule diameter of at least 3 mm) or specific IgE > 0.70 KUA/L, at least against one allergen.
- Participants must have a clinical history of positive response to oral antihistamine treatment
- Participants must have a T5CSS score ≥ 8 points (out of 15) instantaneous symptoms at the screening visit
- Participants must have at least one analytical determination (haemogram, biochemistry) prior to entering in the study without clinically relevant abnormalities. Should there have been any past anomalies, it should be verified and documented with the corresponding analytical determination that they have been normalized and presents values within the normal range before inclusion in the study.
You likely can't join if
- Rhinitis of non-allergic origin.
- Current or planned consumption of grapefruit, apple, orange, or other fruit juices known to affect drug absorption during the treatment period.
- Any relevant clinical condition (or history) of renal, hepatic, gastrointestinal, cardiovascular, respiratory, hematologic, endocrine, or neurologic disease that would preclude the child from being suitable for participate in the study or that may interfere with the objectives of the study, in the opinion of the investigator.
- Clinically relevant abnormalities in laboratory parameters (including ECG abnormalities) indicative of disease, in the opinion of the investigator.
- Children or parents/LAR of the children unable to comply with the requirements of the study (attendance at visits), or children unable to adequately take the study treatment
- Participation in another clinical trial within 30 days prior to ingestion of the first dose of study medication.
See the full eligibility criteria
Who can join
- Participants of either sex (male or female) aged ≥ 6 and < 12 years with a body weight of at least 15 kg at the time of enrolment
- Participants must have a documented clinical history (at least 1 year) of AR and must present mild-moderate clinical symptoms at the time of inclusion in the study
- Participants with AR must have a positive skin reaction/RAST test documented in their clinical history within a year prior to the date of their inclusion in the study: a positive prick test (papule diameter of at least 3 mm) or specific IgE > 0.70 KUA/L, at least against one allergen.
- Participants must have a clinical history of positive response to oral antihistamine treatment
- Participants must have a T5CSS score ≥ 8 points (out of 15) instantaneous symptoms at the screening visit
- Participants must have at least one analytical determination (haemogram, biochemistry) prior to entering in the study without clinically relevant abnormalities. Should there have been any past anomalies, it should be verified and documented with the corresponding analytical determination that they have been normalized and presents values within the normal range before inclusion in the study.
- Participants should have a 12-lead ECG without clinically relevant abnormalities.
- Written consent must be obtained from parents/LAR of the children for them to be included in the study. A signed assent form might be obtained from the participants, if required
What rules you out
- Rhinitis of non-allergic origin.
- Current or planned consumption of grapefruit, apple, orange, or other fruit juices known to affect drug absorption during the treatment period.
- Any relevant clinical condition (or history) of renal, hepatic, gastrointestinal, cardiovascular, respiratory, hematologic, endocrine, or neurologic disease that would preclude the child from being suitable for participate in the study or that may interfere with the objectives of the study, in the opinion of the investigator.
- Clinically relevant abnormalities in laboratory parameters (including ECG abnormalities) indicative of disease, in the opinion of the investigator.
- Children or parents/LAR of the children unable to comply with the requirements of the study (attendance at visits), or children unable to adequately take the study treatment
- Participation in another clinical trial within 30 days prior to ingestion of the first dose of study medication.
- Any other characteristic of the participant or his/her environment, which in the investigator's judgment makes him/her unsuitable to participate in the study (e.g., detection or suspicion of drug or other substance abuse; if participation in the study may harm the child's health, etc.).
- Administration of drugs with sedative properties
- Known allergy and/or hypersensitivity to H1 antihistamines (specifically to the study medications -bilastine - or to their inactive ingredients) or to benzimidazoles
- Participants who are taking or have taken any of the following medications prior to inclusion in the study and who have not complied with the specific washout period indicated below: a. Oral and nasal corticosteroids (within the 30 days before inclusion) b. Topical ocular or nasal antihistamines (within the 7 days before inclusion) c. Systemic antihistamines: i. loratadine and desloratadine: 10 days before inclusion ii. dexchlorpheniramine: 8 days before inclusion iii. ebastine and hydroxyzine: 6 days before inclusion iv. bilastine, fexofenadine, promethazine, cyproheptadine, oxatomide and clemastine: 5 days before inclusion v. cetirizine and levocetirizine: 3 days before inclusion vi. rupatadine: 2 days before inclusion d. Decongestants, anticholinergics (nasal spray or drops) (within the 3 days before inclusion) e. Anti-leukotrienes (within the 7 days before inclusion) f. Ketotifen (within the 2 weeks before inclusion) g. Delayed-acting corticosteroids (within the 3 months before inclusion) h. Macrolide antibiotics and imidazole fungicides (systemic) (within the 7 days before inclusion) i. Investigational medication or antibodies (within the 30 days before inclusion)
- Participants with asthma treated with treatments other than β2 inhaled agonists
- 6. Participants under treatment with drugs that are contraindicated or interact with the study drugs according to its SmPC, such as P-glycoprotein inhibitors (ketoconazole, erythromycin, cyclosporine, diltiazem), anticholinergics, drugs that prolong the QT interval and/or induce Torsade de Pointes, such as class IA antiarrhythmics (quinidine, etc. ) and class III (amiodarone, etc.), antipsychotics (haloperidol), antidepressants (citalopram, etc.), antimalarials (mefloquine, etc.), antibiotics (such as moxifloxacin) and antifungals (such as pentamidine). The association with some gastrointestinal drugs (such as prucalopride), cancer drugs (e.g. toremifene) or methadone should also be avoided.
- Participants under treatment with Allergen-Specific Immunotherapy in the two years prior to inclusion in the study.
- Participants under treatment with stimulant drugs and/or Central Nervous System depressants.
- Girls with menarche.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.